Alzheimer's disease (AD) - Epidemiology Forecast - 2032

This ‘Alzheimer's Disease - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Alzheimer's disease, historical and forecasted epidemiology, and the Alzheimer's disease trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Alzheimer's Disease Understanding

Alzheimer's disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by the gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms, for most people, first appear in their mid-60s. However, early disease may manifest in quadragenarians as well.

Although the symptoms vary widely, they develop slowly and worsen over time. Early signs may include forgetfulness, difficulty with problem-solving or completing familiar tasks, confusion, disorientation, and changes in mood or behavior. As the disease progresses, individuals may experience severe memory loss, language problems, impaired judgment, personality changes, and a decline in overall cognitive abilities.

Improved disease understanding demonstrates that two microscopic features, amyloid plaques and neurofibrillary agglomerates, characterize the disease. The exact cause is mostly unknown, but research indicates that progressive cognitive decline is associated with the accumulation of amyloid-beta (Aß) and tau proteins. These deposits form amyloid protein plaques outside the brain cells and tangles of tau protein within the brain cells.

These plaques and tangles disrupt normal communication between brain cells, leading to progressive degeneration, memory deterioration, and death. Increasing age and family history are important risk factors.

The disease progresses through several stages with a corresponding increase in severity. The preclinical stage is mostly asymptomatic, while in the next mild cognitive impairment stage, an individual may experience mild memory problems, but this may not significantly affect daily functioning, and some individuals with MCI may not progress to Alzheimer's disease. Mild, moderate, and severe stages are associated with progressive deterioration of memory that affects language, personality, or cognitive control, with symptoms interfering with daily life.

Alzheimer's Disease Diagnosis

The pathogenesis is multifactorial, and due to the continuous discovery of novel signaling pathways, various diagnostic tools have revolutionized and improved disease diagnosis making it more personalized. This has helped me understand the various possibilities of tau and amyloid deposition, neurodegeneration, and symptom manifestation.

Diagnosing Alzheimer's disease involves a comprehensive evaluation of medical history, cognitive tests, neurological exams, and assessment of behavioral and functional changes. There is no single test for the diagnosis. Clinical practice typically diagnoses it by a multi-disciplinary workup based on patient history, clinical symptoms, and various neuropsychiatric, physical, and functional assessments. Imaging (computed tomography, magnetic resonance imaging (MRI), positron emission tomography (PET) assessments, and blood tests are particularly important to rule out certain other causes of dementia. PET scans, especially amyloid scans, fluorodeoxyglucose imaging, and tau imaging, besides CSF biomarkers and blood-biomarker-based diagnosis, have improved the diagnosis manifold
For cognitive and functional assessment, standardized tests such as the Mini-Mental State Examination (MMSE) or the Montreal Cognitive Assessment (MoCA) are commonly used. The diagnostic guideline provided by National Institute on Aging (NIA), called NIA-AA criteria, is the most accepted.

Alzheimer's Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the total diagnosed prevalent cases of Alzheimer's disease, age-specific cases of Alzheimer's disease, gender-specific cases of Alzheimer's disease, and severity-specific cases of Alzheimer's disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Alzheimer's Disease Detailed Epidemiology Segmentation

• As per the estimates by the publisher, in 2022, the total diagnosed prevalent cases of Alzheimer's disease were estimated to be approximately 15,083,370 cases in the 7MM. These cases are projected to increase at a CAGR of 2.4%.
• In the US, there were approximately 6,186,284 diagnosed prevalent cases of Alzheimer's disease in 2022. These were nearly 41% of the total cases in the 7MM. These cases are expected to increase during the forecast period.
• In 2022, among the 7MM, Japan accounted for the second-highest diagnosed prevalent cases of Alzheimer's disease, contributing nearly 26%, while the UK accounted for the least with nearly 4% of the total diagnosed prevalent cases.
• In 2022, EU4 and the UK accounted for nearly 33% of the total diagnosed prevalent cases of Alzheimer's in the 7MM. There were approximately 4,942,376 total diagnosed prevalent cases of Alzheimer's disease.
• Among EU4 and the UK, Germany accounted for the highest (nearly 31%) total diagnosed prevalent cases of Alzheimer's disease, with approximately 1,510,515 cases, followed by France (nearly 24%).
• Japan accounted for 3,954,710 diagnosed prevalent cases of Alzheimer's disease. In 2022 the age-specific distribution of the disease suggests that the age cohort of 75-84 years accounted for the majority, nearly 51% of the cases, followed by =85 (32%), 65-74 (14%), and < 65 years (3%). These cases of Alzheimer's disease are expected to increase during the forecast period.
• As per estimates based on this epidemiology model for Alzheimer's disease, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately 5,024,849 male and 10,058,521 female cases in the 7MM in 2022.
• According to estimates based on this epidemiology model, in EU4 and the UK, around 1,454,541 males and 3,487,835 females were diagnosed with Alzheimer's disease in 2022, and the cases are expected to increase during the forecast period.
• Alzheimer's disease diagnosed prevalent cases based on severity were divided into MCI, mild, moderate, and severe dementia. According to the publisher's epidemiology model, in the 7MM, MCI due to Alzheimer's disease accounted for the highest cases, with approximately 8,174,943 cases, while severe dementia accounted for the least, with approximately 1,450,356 cases in 2022. The cases are expected to increase by 2032.
• According to estimates based on this epidemiology model for Alzheimer's disease, in Japan, in 2022, there were approximately 2,324,183 cases of MCI, 826,139 cases of mild dementia, 517,671 cases of moderate dementia, and 286,716 cases of severe dementia, which are expected to increase during the study period.

Scope of the Report

• The report covers a descriptive overview of Alzheimer's disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Alzheimer's disease.
• The report recognizes the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, total diagnosed prevalent cases of Alzheimer's disease, age-specific cases of Alzheimer's disease, gender-specific cases of Alzheimer's disease, and severity-specific cases of Alzheimer's disease.

Report Highlights

• Ten Years Forecast of Alzheimer's Disease
• The 7MM coverage
• Total Diagnosed Prevalent Cases of Alzheimer's Disease
• Age-specific Cases of Alzheimer's Disease
• Gender-specific Cases of Alzheimer's Disease
• Severity-specific Cases of Alzheimer's Disease

Key Questions Answered

• What are the disease risk and burdens of Alzheimer's disease?
• What is the historical Alzheimer's disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of Alzheimer's disease at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with Alzheimer's disease?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Alzheimer's disease during the forecast period (2023-2032)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Reasons to Buy

The Alzheimer's disease report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM Alzheimer's disease epidemiology forecast.
• The Alzheimer's disease epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Alzheimer's disease epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032